ibrutinib
janssen,abbvie
['ibru', 'cll']
ccl12 trial: ibrutinib v.s. placebo in asymptomatic, treatment-naive early-stage cll #17icml - ibrutinib associated with cardiac and bleeding events - no improve on os
- w&amp;w still remains the best option on asymptomatic patients 
Research Fellow @MSKCancerCenter Hematologist @hospitalclinic #Lymphoma #CLL.